Brain tumor cocktail: could a 4-Drug combo tame glioblastoma?

NCT ID NCT05083754

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether combining a chemotherapy wafer placed in the brain during surgery with an immunotherapy drug and standard radiation (with or without another chemo pill) is safe and feasible for people with newly-diagnosed glioblastoma. About 50 adults who have already had the wafer placed will receive the combination. The main goal is to find the safest dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carmustine wafer, retifanlimab, temozolomide, radiation therapy
What this could lead to: If this works, it could point toward a more effective treatment for glioblastoma that combines chemotherapy, immunotherapy, and radiation.
What could go wrong: This is a very early Phase 1 trial with only 50 people, so it is mainly checking safety and dosing. The combination may cause serious side effects and might not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1 gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Johns Hopkins Medical Institution
RECRUITING

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.